GCM
INO icon

Graham Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

Graham Capital Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-62,567
Closed -$114K – 1390
2024
Q4 		$114K Buy
+62,567
New +$277K ﹤0.01% 1143
2024
Q3 		– Sell
-12,712
Closed -$103K – 1205
2024
Q2 		$103K Buy
+12,712
New +$134K ﹤0.01% 943
2023
Q2 		– Sell
-2,948
Closed -$29K – 1127
2023
Q1 		$29K Buy
+2,948
New +$50.3K ﹤0.01% 1014
2022
Q4 		– Sell
-4,778
Closed -$98K – 1167
2022
Q3 		$98K Buy
+4,778
New +$122K ﹤0.01% 1026

Other funds holding INO

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Graham Capital Management's INO Position: Q1 2025 in Review

Graham Capital Management sold out of Inovio Pharmaceuticals (INO) in Q1 2025, closing a stake of 62,567 shares — an estimated $114K sold.

Graham Capital Management first reported a position in INO in Q3 2022 and held it in 4 quarters. The position peaked at $114K in Q4 2024. 107 funds tracked by Wall St. Rank hold INO as of Q1 2025.

  • Graham Capital Management reported no remaining Inovio Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Graham Capital Management sold 62,567 Inovio Pharmaceuticals shares in Q1 2025, an estimated $114K.
  • Graham Capital Management first reported a position in Inovio Pharmaceuticals in Q3 2022 and held it in 4 quarters.
  • Graham Capital Management's Inovio Pharmaceuticals position peaked at $114K in Q4 2024.
  • 107 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2025.

Based on Graham Capital Management's 13F filing for Q1 2025, filed 15 May 2025.